4-氨基-N-[4-(三氟甲基)苄基]苯磺酰胺 | 339-42-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-N-[4-(三氟甲基)苄基]苯磺酰胺
• 英文名称: N¹-(4-trifluoromethylphenyl)sulfanilamide
• 英文别名: N-((4-trifluoromethyl)phenyl)-4-aminobenzene sulphonamide；4-amino-N-(4-(trifluoromethyl)phenyl)benzenesulfonamide；sulfanilic acid-(4-trifluoromethyl-anilide)；Sulfanilsaeure-(4-trifluormethyl-anilid)；4-amino-N-[4-(trifluoromethyl)phenyl]benzenesulfonamide
• CAS: 339-42-4
• 化学式: C₁₃H₁₁F₃N₂O₂S
• 分子量: 316.304
• InChiKey: VRMCQOJYBYDIHX-UHFFFAOYSA-N

物化性质

• 熔点：
  178.55-179 °C
• 沸点：
  440.2±55.0 °C(Predicted)
• 密度：
  1.475±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 海关编码：
  2935009090

SDS

4-氨基-正-[4-(三氟甲基)苯基]苯磺酰胺MSDS英文版

反应信息

• 作为反应物：
  描述：

  4-氨基-N-[4-(三氟甲基)苄基]苯磺酰胺 在 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.08h， 生成 N-((4-trifluoromethyl)phenyl)-4-(phenylureido)benzene sulphonamide mono sodium salt
  参考文献：
  名称：

  脲基基团作为基于Ureido的阴离子受体中的电子吸收单元：增强的阴离子络合与去质子化。

  摘要：

  磺酰胺基团被用作吸电子基团，以增强基于尿素的受体的阴离子络合特征。合成并彻底测试了一系列磺酰胺基和尿素NH基团的酸度变化的受体。各个络合性质反映了给定分子中作为取代的函数的去质子/络合平衡。含有缀合sulphonamidic部分给电子基团的受体显示出朝向h时缔合常数2 PO 4 -和羧酸根阴离子，而那些含有吸电子基团倾向于sulphonamidic N中的去质子化ħ。可以通过在受体合成的早期阶段进行烷基化来避免去质子化问题，也可以将其用于插入合适的基团，从而使其锚定在各种底物上，从而形成更精细的受体结构。

  DOI：

  10.1002/cplu.202000326
• 作为产物：
  描述：

  4-硝基三氟甲苯 在 吡啶 、 乙醇 、 镍 作用下， 生成 4-氨基-N-[4-(三氟甲基)苄基]苯磺酰胺
  参考文献：
  名称：

  合成抗疟药；磺胺的某些衍生物的制备。

  摘要：

  DOI：

  10.1021/ja01212a070

文献信息

• Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors
  作者：Flávia F. Silveira、Juliana O. de Souza、Lucas V.B. Hoelz、Vinícius R. Campos、Valquíria A.P. Jabor、Anna C.C. Aguiar、M. Cristina Nonato、Magaly G. Albuquerque、Rafael V.C. Guido、Nubia Boechat、Luiz C.S. Pinheiro

  DOI：10.1016/j.ejmech.2020.112941

  日期：2021.1

  pyrazolopyrimidine and quinoline derivatives as P. falciparum inhibitors (3D7 strain). Thirty compounds exhibited anti-P. falciparum activity, with IC50 values ranging from 0.030 to 9.1 μM. The [1,2,4]triazolo[1,5-a]pyrimidine derivatives were more potent than the pyrazolo[1,5-a]pyrimidine and quinoline analogues. Compounds 20, 21, 23 and 24 were the most potent inhibitors, with IC50 values in the range of 0.030

  在这项工作中，我们设计并合成了35种新的三唑并嘧啶，吡唑并嘧啶和喹啉衍生物作为恶性疟原虫抑制剂（3D7株）。三十种化合物表现出抗恶性疟原虫活性，IC 50值范围为0.030至9.1μM。[1,2,4]三唑并[1,5- a ]嘧啶衍生物比吡唑并[1,5- a ]嘧啶和喹啉类似物更有效。化合物20，21，23和24是最有效的抑制剂，具有IC 50值在0.030-0.086μM范围内，与氯喹等效。此外，这些化合物具有选择性，对人肝癌细胞系HepG2没有细胞毒活性。所有的[1,2,4]三唑并[1,5- a ]嘧啶衍生物均在低微摩尔至低纳摩尔范围（IC 50值为0.08-1.3μM）内抑制Pf DHODH活性，并且未显示出对Hs DHODH的明显抑制作用同源物（50μM时为0-30％）。分子对接研究表明[1,2,4]三唑并[1,5- a ]嘧啶衍生物与Pf DHODH的结合方式，与Pf DHODH酶
• PROTEIN KINASE INHIBITORS
  申请人：Bearss David J.

  公开号：US20080207632A1

  公开（公告）日：2008-08-28

  Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer, such as Aurora kinase-expressing cancers and Axl kinase-expressing cancers. Compounds of the invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , X, Z, L 2 and w are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

  本发明揭示了蛋白激酶抑制剂，其在治疗蛋白激酶介导的疾病和病状中具有功效，例如癌症，如Aurora激酶表达的癌症和Axl激酶表达的癌症。本发明的化合物具有以下结构：包括立体异构体、前药和其药学上可接受的盐，其中R1、R2、R3、X、Z、L2和w如本文所定义。本发明还揭示了含有本发明化合物的组合物，以及与其使用相关的方法。
• INHIBITORS OF BROMODOMAINS AS MODULATORS OF GENE EXPRESSION
  申请人：Zhou Ming-Ming

  公开号：US20140066410A1

  公开（公告）日：2014-03-06

  This disclosure relates generally to compounds and compositions comprising one or more diphenylethylene, diphenylethylyne, and azobenzene analogs. These compounds are useful for treating diseases associated with NF-kB and p53 activity, such as cancer and inflammatory disease.

  本公开涉及一种化合物和组合物，其中包括一种或多种二苯乙烯，二苯乙炔和偶氮苯类似物。这些化合物可用于治疗与NF-kB和p53活性相关的疾病，如癌症和炎症性疾病。
• WO2008/55233
  申请人：——

  公开号：——

  公开（公告）日：——
• Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains
  作者：Guangtao Zhang、Alexander N. Plotnikov、Elena Rusinova、Tong Shen、Keita Morohashi、Jennifer Joshua、Lei Zeng、Shiraz Mujtaba、Michael Ohlmeyer、Ming-Ming Zhou

  DOI：10.1021/jm401334s

  日期：2013.11.27

  BRD4, characterized by two acetyl-lysine binding bromodomains and an extra-terminal (ET) domain, is a key chromatin organizer that directs gene activation in chromatin through transcription factor recruitment, enhancer assembly, and pause release of the RNA polymerase II complex for transcription elongation. BRD4 has been recently validated as a new epigenetic drug target for cancer and inflammation. Our current knowledge of the functional differences of the two bromodomains of BRD4, however, is limited and is hindered by the lack of selective inhibitors. Here, we report our structure-guided development of diazobenzene-based small-molecule inhibitors for the BRD4 bromodomains that have over 90% sequence identity at the acetyl-lysine binding site. Our lead compound, MS436, through a set of water-mediated interactions, exhibits low nanomolar affinity (estimated Ki of 30-50 nM), with preference for the first bromodomain over the second. We demonstrated that MS436 effectively inhibits BRD4 activity in NF-κB-directed production of nitric oxide and proinflammatory cytokine interleukin-6 in murine macrophages. MS436 represents a new class of bromodomain inhibitors and will facilitate further investigation of the biological functions of the two bromodomains of BRD4 in gene expression.